3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Pancreatic Neoplasms
57
Carcinoma, Non-Small-Cell Lung
34
Urinary Bladder Neoplasms
31
Neoplasm Metastasis
20
Lung Neoplasms
19
Ovarian Neoplasms
18
Lymphoma, Large B-Cell, Diffuse
18
Cholangiocarcinoma
15
Biliary Tract Neoplasms
14
Triple Negative Breast Neoplasms
13
Neoplasms
13
Nasopharyngeal Carcinoma
13
Colorectal Neoplasms
12
Breast Neoplasms
12
Carcinoma, Transitional Cell
11
Non-Muscle Invasive Bladder Neoplasms
10
Recurrence
9
Fallopian Tube Neoplasms
9
Gallbladder Neoplasms
8
Sarcoma
6
Parkinson Disease 4, Autosomal Dominant Lewy Body
6
Bile Duct Neoplasms
6
Uterine Cervical Neoplasms
5
Osteosarcoma
5
Lymphoma, Non-Hodgkin
5
Lymphoma
5
Endometrial Neoplasms
5
Melanoma
4
Hodgkin Disease
4
Colonic Neoplasms
4
Interventions
X-Rays
6
Phantoms, Imaging
6
Magnetic Resonance Spectroscopy
6
Specimen Handling
5
Nuclear Medicine Department, Hospital
5
Biopsy
4
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
erdafitinib
2
ensartinib
2
LY3023414
2
talazoparib
1
olaparib
1
irinotecan sucrosofate
1
amino-acid, glucose, and electrolyte solution
1
Vemurafenib
1
Temozolomide
1
Pharmacogenomic Variants
1
Liquid Biopsy
1
177Lu-octreotide, DOTA(0)-Tyr(3)-
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Neuroectodermal Tumors, Primitive, Peripheral
×
Gemcitabine
×
90 days
×
Clear all
No trials found.